title: Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma.
abstract: The long median survival time of patients with follicular non-Hodgkin's lymphoma (NHL), means that the efficacy of new treatments are difficult to assess in the short term. Bcl-2 is an inhibitor of apoptosis and overexpression of the bcl-2 gene in the blood or bone marrow is a feature in up to 85% of patients with follicular NHL. Levels of bcl-2(+) cells in the peripheral blood or bone marrow therefore are a useful measure of disease status in such patients and can be detected by polymerase chain reaction (PCR). Complete bcl-2 clearance from the bone marrow (molecular remission) following autologous stem cell transplant (ASCT) for follicular NHL is considered to be an important prognostic factor for disease-free survival. Tumour cell contamination of the stem cell grafts used in ASCT is commonly associated with relapse. This can be addressed by purging the stem cell harvest prior to transplantation. Various methods of in vitro purging after stem cell collection have been shown to reduce the level of contamination but yield is invariably reduced and grafts remain bcl-2 positive. However, in vivo purging with rituximab during the process of collection has been used to obtain bcl-2-negative stem cell harvests without compromising the yield. Rituximab is a monoclonal antibody licensed for treatment of relapsed and refractory low-grade or follicular NHL. Rituximab targets the CD20 antigen, which is found on cells of the B cell lineage. When used for in vivo purging it depletes the peripheral blood of CD20-positive cells and prevents contamination by lymphoma cells. Molecular remission, as measured by bone-marrow bcl-2 clearance, has been achieved in 7/7 patients with follicular NHL at 1 year after treatment with ASCT using rituximab as an 'in vivopurse', followed by rituximab maintenance. Early clinical outcomes are also encouraging.
authors.affiliation: Advanced Therapeutics Program, Toronto-Sunnybrook Regional Cancer Centre and Sunnybrook and Women's College Health Centre, Toronto, Ontario, Canada. neil.berinstein@tsrcc.on.ca
authors.forename: N L
authors.initials: NL
authors.lastname: Berinstein
authors.forename: R
authors.initials: R
authors.lastname: Buckstein
authors.forename: K
authors.initials: K
authors.lastname: Imrie
authors.forename: D
authors.initials: D
authors.lastname: Spaner
authors.forename: J
authors.initials: J
authors.lastname: Mangel
authors.forename: K
authors.initials: K
authors.lastname: Tompkins
authors.forename: N
authors.initials: N
authors.lastname: Pennell
authors.forename: M
authors.initials: M
authors.lastname: Reis
authors.forename: P
authors.initials: P
authors.lastname: Pavlin
authors.forename: A
authors.initials: A
authors.lastname: Lima
authors.forename: A
authors.initials: A
authors.lastname: Couvadia
authors.forename: J
authors.initials: J
authors.lastname: Robinson
authors.forename: P
authors.initials: P
authors.lastname: Richardson
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D001853:Bone Marrow / Q000737:chemistry / Q000473:pathology; D016465:Bone Marrow Purging / Q000379:methods; D006801:Humans; D008224:Lymphoma, Follicular / Q000473:pathology* / Q000628:therapy; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D019253:Proto-Oncogene Proteins c-bcl-2; D000069283:Rituximab